Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Abstract Background Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the management of hematologic toxicities. A previous pooled analysis from the PALOM...

Full description

Bibliographic Details
Main Authors: Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Breast Cancer Research
Subjects:
Palbociclib
Adverse event management
Neutropenia
Dose reductions
Dose modification
Online Access:http://link.springer.com/article/10.1186/s13058-020-01263-0

Internet

http://link.springer.com/article/10.1186/s13058-020-01263-0

Similar Items